Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026
Same author

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

British journal of haematology·2026
Same author

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities.

Transplantation and cellular therapy·2026
Same author

CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML.

Transplantation and cellular therapy·2026
Same author

HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.

British journal of haematology·2026

Related Experiment Video

Updated: Jun 23, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Meletios Dimopoulos1, Andrew Spencer, Michael Attal

  • 1University of Athens School of Medicine, Athens, Greece. mdimop@med.uoa.gr

The New England Journal of Medicine
|November 23, 2007
PubMed
Summary

Lenalidomide plus dexamethasone significantly improved outcomes for relapsed or refractory multiple myeloma patients. This combination therapy demonstrated longer time to progression and improved survival compared to placebo.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: Jun 23, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Hematology
  • Clinical Oncology
  • Pharmacology

Background:

  • Lenalidomide, a thalidomide analogue, exhibits potent biologic activity.
  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • Relapsed or refractory multiple myeloma presents a significant therapeutic challenge.

Purpose of the Study:

  • To evaluate the efficacy of lenalidomide in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
  • To compare the efficacy of lenalidomide plus dexamethasone versus placebo plus dexamethasone in this patient population.

Main Methods:

  • A phase 3, placebo-controlled trial involving 351 patients with relapsed or refractory multiple myeloma.
  • Patients received either oral lenalidomide (25 mg) or placebo, both in conjunction with oral dexamethasone.
  • Treatment continued until disease progression or unacceptable toxicity, with time to progression as the primary endpoint.

Main Results:

  • The lenalidomide group showed a significantly longer median time to progression (11.3 months vs. 4.7 months; P<0.001).
  • Complete or partial response rates were higher in the lenalidomide group (60.2% vs. 24.0%; P<0.001), including complete responses (15.9% vs. 3.4%; P<0.001).
  • Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03), despite increased rates of neutropenia, thrombocytopenia, and venous thromboembolism.

Conclusions:

  • Lenalidomide combined with dexamethasone is a more effective treatment for relapsed or refractory multiple myeloma than high-dose dexamethasone alone.
  • The combination therapy offers significant benefits in terms of progression-free survival and overall survival.
  • Adverse events, including neutropenia and venous thromboembolism, require careful monitoring in patients receiving lenalidomide plus dexamethasone.